Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
We are engaged in the development and commercialization of the patented technology which we license. We are currently sponsoring a clinical trial in the US. Our principal operations are focused on developing innovative cell therapy products focused on the treatment of blood cancers and nonmalignant ... We are engaged in the development and commercialization of the patented technology which we license. We are currently sponsoring a clinical trial in the US. Our principal operations are focused on developing innovative cell therapy products focused on the treatment of blood cancers and nonmalignant blood disorders as well as the facilitation of safer and more accessible organ transplantations. Show more
Ask ADVFN Intelligence (AI)
NEW YORK, NY / ACCESSWIRE / May 20, 2015 / Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.027725 | 4.84469878992 | 0.572275 | 0.6 | 0.35 | 6600 | 0.54879494 | CS |
| 4 | -0.09 | -13.0434782609 | 0.69 | 0.7 | 0.139 | 13396 | 0.56284116 | CS |
| 12 | 0.16 | 36.3636363636 | 0.44 | 0.75 | 0.139 | 23185 | 0.39696246 | CS |
| 26 | 0.5992 | 74900 | 0.0008 | 0.75 | 0.0008 | 18043 | 0.39572144 | CS |
| 52 | 0.2298 | 62.074554295 | 0.3702 | 0.75 | 0.0002 | 14954 | 0.41017205 | CS |
| 156 | -0.94 | -61.038961039 | 1.54 | 1.89 | 0.0002 | 12190 | 0.5085876 | CS |
| 260 | -0.29 | -32.5842696629 | 0.89 | 2.55 | 0.0002 | 9242 | 0.77126257 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
